论文部分内容阅读
目的:观察熊去氧胆酸、铝碳酸镁、莫沙必利对胆汁反流性残胃炎的临床疗效,并分析其作用机制。方法:55例胆汁反流性残胃炎患者随机分为2组:A组27例口服莫沙必利和铝碳酸镁;B组28例口服熊去氧胆酸、莫沙必利和铝碳酸镁。治疗4周后观察腹痛、腹胀、烧心、呕吐胆汁等症状积分和复查胃镜下的炎症积分改变。结果:治疗后症状积分除A组的腹胀外均明显下和,2组胃镜积分也明显下降(P<0.05),2组的症状积分下降值之间的比较,B组显著低于A组(P<0.05)。胃腔内胆汁积分下降值之间的比较,差异无显著性(P>0.05)。结论:熊去氧胆酸联合莫沙必利和铝碳酸镁能有效治疗胆汁反流性残胃炎。
Objective: To observe the clinical effect of ursodeoxycholic acid, magnesium aluminum carbonate and mosapride on bile reflux residual gastritis and to analyze its mechanism. Methods: Fifty-five patients with bile reflux gastritis were randomly divided into two groups: 27 patients in group A received mosapride and magnesium aluminum carbonate; and 28 patients in group B took ursodeoxycholic acid, mosapride and magnesium aluminum carbonate orally. After 4 weeks of treatment, abdominal pain, abdominal distension, heartburn and vomiting of bile were observed, and the inflammation scores under endoscopy were changed. Results: After treatment, the symptom scores were significantly lower than those in group A, and the scores of gastroscope were significantly decreased in both groups (P <0.05). The scores of symptom scores in group B were significantly lower than those in group A P <0.05). There was no significant difference in the decrease of intragastric bile integral (P> 0.05). Conclusion: Ursodeoxycholic acid combined with mosapride and magnesium aluminum carbonate can effectively treat bile reflux gastritis.